Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6639359 | 0.81 | PIK3CD (0.37) | PIK3CD | |
| SCHEMBL10855532 | 0.81 | PARP1 (0.39) | PIK3CD | |
| SCHEMBL13548275 | 0.79 | FGFR1 (0.34) | PIK3CDHSD17B10KDR | |
| SCHEMBL13547873 | 0.77 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL10559790 | 0.75 | HRH3 (0.38) | — | |
| SCHEMBL2852675 | 0.75 | HRH1 (0.39) | PIK3CD | |
| SCHEMBL3662694 | 0.73 | PARP1 (0.34) | PIK3CD | |
| SCHEMBL2847867 | 0.73 | NR4A2 (0.40) | CDK8HSD17B10 | |
| SCHEMBL2844615 | 0.73 | MEN1 (0.40) | PIK3CDKDR | |
| SCHEMBL6930393 | 0.73 | PIK3CD (0.35) | PIK3CDCA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
| EP-0734387-B1 | HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-0915847-A4 | SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0784698-A4 | BIOLOGICAL RESOLUTION OF RACEMIC INDENE OXIDE TO (1S,2R)-INDENE OXIDE | MERCK & CO INC (US) | 1999-07-14 | — | — | EP | disclosed |
| EP-0915847-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004526-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0784698-A1 | BIOLOGICAL RESOLUTION OF RACEMIC INDENE OXIDE TO (1S,2R)-INDENE OXIDE | Merck & Co., Inc. (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5650412-A | VIRICIDES, IMMUNOMODULATORS, ANTIBIOTICS OR VACCINES | MERCK & CO., INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5646148-A | PIPERAZINYLBENZOFURAN DERIVATIVES | MERCK & CO., INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0734387-A4 | HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 1997-03-05 | — | — | EP | disclosed |
| EP-0734387-A1 | HIV PROTEASE INHIBITORS | MERCK & CO. INC. (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1996012818-A1 | BIOLOGICAL RESOLUTION OF RACEMIC INDENE OXIDE TO (1S,2R)-INDENE OXIDE | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| US-5489685-A | CATALYTIC REACTION OF TRIMETHYLSILYLACETYLENE WITH HALOGENATED HYDROXY PYRIDINE ESTER, THEN INCUBATION WITH ACID AND TREATMENT WITH STRONG BASE OR HALIDE FOR CYCLIZATION | MERCK & CO., LTD. (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995016688-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | RECQL 302/4885CDK8 3362/4885PIK3CD 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.